RLD2001-1

DRUG4 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

Hypertension

Phase 3

Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients

CompletedNCT04820907

Hanmi Pharmaceutical Company LimitedHypertension

Start: 2020-10-27End: 2021-09-30Updated: 2023-09-22

Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients

CompletedNCT05199129

Hanmi Pharmaceutical Company LimitedHypertension

Start: 2021-11-17End: 2022-09-14Updated: 2023-09-22

A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension

CompletedNCT06438172

Hanmi Pharmaceutical Company LimitedHypertension

Start: 2024-03-25End: 2024-12-02Updated: 2025-02-19

A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

Not yet recruitingNCT07660796

Hanmi Pharmaceutical Company LimitedHypertension

Start: 2026-07-06End: 2027-11-30Target: 256Updated: 2026-06-30